Compare Cassava Sciences Inc (FLNA) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hasbro, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Hasbro, Inc. trades at $93.32 (market cap $13.05B). The key difference: Hasbro, Inc. is far larger — about 331.2× Cassava Sciences Inc's market cap, and Hasbro, Inc. pays a 3.03% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Hasbro, Inc. for 97 Days on average.
| FLNA | HAS | |
|---|---|---|
Market Cap | $39.40M | $13.05B |
Volume | 759,018 | 1,207,655 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $105.88 |
52-Week Low | $0.68 | $70.95 |
Typical Hold Time | 37 Days | 97 Days |
Enterprise Value | -$43.28M | $15.24B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Hasbro (HAS) trades at $93.32, up 2.83% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with recent earnings beats but negative 2025 net income of -$322.4M. Revenue growth is projected to reach $5.0B in 2026 with improved profitability. Analyst consensus is bullish with a $107.60 price target and no sell ratings among 33 analysts. Recent news highlights Magic: The Gathering's strong performance and upcoming Q3 2026 earnings release on October 20.
Investment outlook remains positive driven by gaming segment growth and cost savings initiatives, though risks include high debt levels (59.09% debt-to-asset ratio) and competitive pressures. The stock's current valuation at 16.46 P/E appears reasonable given projected earnings recovery. Upside potential exists toward the $107.60 consensus target if Q3 earnings meet expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
